Get the Stockscreener App
5.77
8.46%
0.45
Salarius Pharmaceuticals Inc stock is traded at $5.77, with a volume of 36,043.
It is up +8.46% in the last 24 hours and down -45.84% over the past month.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
See More
Previous Close:
$5.32
Open:
$5.28
24h Volume:
36,043
Relative Volume:
0.19
Market Cap:
$3.40M
Revenue:
$4.70M
Net Income/Loss:
$-4.99M
P/E Ratio:
-0.8988
EPS:
-6.42
Net Cash Flow:
$-5.29M
1W Performance:
-16.70%
1M Performance:
-45.84%
6M Performance:
-71.29%
1Y Performance:
-79.32%
1-Day Range:
$5.18
$5.99
1-Week Range:
$4.76
$7.10
52-Week Range:
$4.76
$108.00
Salarius Pharmaceuticals Inc Stock (SLRX) Company Profile
Name
Salarius Pharmaceuticals Inc
Sector
Industry
Phone
346-772-0346
Address
2450 HOLCOMBE BLVD, HOUSTON
Compare SLRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLRX
Salarius Pharmaceuticals Inc
|
5.77 | 3.40M | 4.70M | -4.99M | -5.29M | -6.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Salarius Pharmaceuticals Inc Stock (SLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-20 | Initiated | Ladenburg Thalmann | Buy |
Salarius Pharmaceuticals Inc Stock (SLRX) Latest News
What recovery options are there for Salarius Pharmaceuticals Inc.Earnings Beat & AI Enhanced Execution Alerts - Newser
Market reaction to Salarius Pharmaceuticals Inc.’s recent newsJuly 2025 Breakouts & Precise Trade Entry Recommendations - Newser
Is Salarius Pharmaceuticals Inc. in Accumulation Phase Now2025 Valuation Update & Fast Entry Momentum Alerts - classian.co.kr
Is Salarius Pharmaceuticals Inc. meeting your algorithmic filter criteriaStop Loss & Precise Swing Trade Alerts - Newser
Identifying reversal signals in Salarius Pharmaceuticals IncJuly 2025 Breakouts & Fast Entry Momentum Alerts - Newser
Is it time to cut losses on Salarius Pharmaceuticals Inc.Portfolio Performance Report & Long Hold Capital Preservation Plans - Newser
Using RSI to spot recovery in Salarius Pharmaceuticals Inc.2025 Analyst Calls & Reliable Volume Spike Alerts - Newser
Identifying reversal signals in Salarius Pharmaceuticals Inc.2025 Bull vs Bear & Real-Time Volume Analysis - Newser
Will Salarius Pharmaceuticals Inc. see short term momentumTrade Signal Summary & Entry Point Strategy Guides - Newser
Will Salarius Pharmaceuticals Inc. continue its uptrendRisk Management & Daily Entry Point Alerts - Newser
Advanced analytics toolkit walkthrough for Salarius Pharmaceuticals Inc.2025 Performance Recap & Technical Entry and Exit Alerts - Newser
Custom watchlist performance reports with Salarius Pharmaceuticals Inc.Weekly Gains Report & Risk Controlled Swing Alerts - Newser
Salarius Pharmaceuticals appoints Mark J. Rosenblum as acting CEO By Investing.com - Investing.com Nigeria
Salarius Pharmaceuticals appoints Mark J. Rosenblum as acting CEO - Investing.com India
Salarius Pharmaceuticals Appoints New Acting CEO - TipRanks
Heatmap analysis for Salarius Pharmaceuticals Inc. and competitorsPortfolio Risk Report & Stepwise Entry and Exit Trade Signals - Newser
Is a relief rally coming for Salarius Pharmaceuticals Inc. holders2025 Volatility Report & Safe Capital Growth Stock Tips - Newser
Upcoming Stock Splits for August 18-22: Salarius, Entero, Chanson, LanzaTech, GIBO - AInvest
What analysts say about Salarius Pharmaceuticals Inc. stock outlookQuarterly Earnings Summary & Weekly Watchlist for Hot Stocks - Newser
Salarius Pharmaceuticals Inc. stock prediction for this weekPortfolio Update Report & Weekly Breakout Opportunity Watchlist - Newser
Visualizing Salarius Pharmaceuticals Inc. stock with heatmapsEarnings Miss & Weekly High Conviction Trade Ideas - Newser
What MACD and RSI say about Salarius Pharmaceuticals Inc.Weekly Loss Report & Weekly Watchlist of Top Performers - Newser
What’s next for Salarius Pharmaceuticals Inc. stock priceTrade Ideas & Weekly Breakout Opportunity Watchlist - Newser
Why Salarius Pharmaceuticals Inc. is moving today2025 Volume Leaders & Technical Analysis for Trade Confirmation - Newser
Technical signs of recovery in Salarius Pharmaceuticals Inc.Market Performance Report & Reliable Breakout Forecasts - Newser
Using data filters to optimize entry into Salarius Pharmaceuticals Inc.Trade Exit Report & Safe Capital Growth Plans - Newser
Salarius Pharmaceuticals' $50M Shelf Filing: A Strategic Move to Fuel High-Unmet-Need Cancer Therapies - AInvest
Published on: 2025-08-16 06:53:45 - Newser
Can you recover from losses in Salarius Pharmaceuticals Inc.2025 Volatility Report & Real-Time Market Trend Scan - Newser
Salarius Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:SLRX - Benzinga
Using Bollinger Bands to evaluate Salarius Pharmaceuticals Inc.Trade Ideas & Low Risk Investment Opportunities - Newser
Regression Model Predicts Rangebound Movement in Salarius Pharmaceuticals Inc.2025 Geopolitical Influence & Growth Oriented Trade Recommendations - sundaytimes.kr
Will Salarius Pharmaceuticals Inc. bounce back from current support2025 Year in Review & Expert Verified Movement Alerts - Newser
Salarius Pharmaceuticals Announces Reverse Stock Split - TipRanks
Salarius Pharmaceuticals To Carry Out 1-for-15 Reverse Stock Split On August 18th, 2025 - 富途牛牛
What’s next for Salarius Pharmaceuticals Inc. stockJuly 2025 Weekly Recap & AI Forecast Swing Trade Picks - 선데이타임즈
Signal strength of Salarius Pharmaceuticals Inc. stock in tech scannersJuly 2025 Drop Watch & Daily Stock Trend Reports - Newser
How Efficient Is Salarius Pharmaceuticals Inc. at Controlling Operating CostsTrade Exit Summary & Reliable Price Breakout Alerts - Newser
How Salarius Pharmaceuticals Inc. stock performs during market volatilityMarket Performance Report & Free Real-Time Volume Trigger Notifications - Newser
Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split - citybiz
Salarius Pharmaceuticals announces 1-for-15 reverse stock split - TipRanks
Salarius Pharmaceuticals To Implement 1-for-15 Reverse Stock Split - Nasdaq
Salarius Pharmaceuticals to implement 1-for-15 reverse stock split By Investing.com - Investing.com Australia
Salarius Pharmaceuticals to implement 1-for-15 reverse stock split - Investing.com
Salarius Pharmaceuticals Inc Stock (SLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):